Xenon Pharmaceuticals Inc.
For the period ended Sep 30, 2025. Filed Nov 3, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 3, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
On August 15, 2025, Dr. Gillian Cannon, a member of the Board of Directors, adopted a trading plan intended to satisfy the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The plan provides that commencing June 5, 2026, Dr. Cannon will sell 45% of the gross shares issued upon the settlement of Dr. Cannon's vesting 2,645 restricted share units at then-prevailing market prices. The plan terminates on the earlier of the date all shares under the trading plan are sold or June 30, 2026.
On August 17, 2025, Dr. Gary Patou, a member of the Board of Directors, adopted a trading plan intended to satisfy the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The plan provides that commencing June 5, 2026, Dr. Patou will sell 50% of the gross shares issued upon the settlement of Dr. Patou's vesting 2,645 restricted share units at then-prevailing market prices. The plan terminates on the earlier of the date all shares under the trading plan are sold or June 30, 2026.
-64-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.